RESET-MG: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB-CD19-CAR T Cell Therapy in Generalized Myasthenia Gravis (gMG) (S14.003)

Ali Habib; Stefan Ciurea; Christina Ulane; Ran Reshef; Min Kang; Madhav Seshadri; David Richman; Mehrdad Abedi; Jonathan Hogan; Yvonne White; Jennifer Gresh; Wayne Hull; Thomas Furmanak; Jenell Volkov; Daniel Nunez; Dan Thompson; Jason Stadanlick; Larissa Ishikawa; Zach Vorndran; Alexandra Ellis; Steve Flanagan; Mallorie Werner; Justin Cicarelli; Jazmean Williams; Danielle Kobulsky; Domenick Braccia; Fatemeh Hadi-Nezhad; Quynh Lam; Samik Basu; Raj Tummala; David Chang

doi:10.1212/wnl.0000000000215393

Key Points

This trial aims to evaluate the safety and efficacy of rese-cel in patients with generalized myasthenia gravis (gMG).
Phase 1/2 trial design
Two independent cohorts based on anti-AChR-antibody status
Trial registered with NCT06359041
Safety and efficacy evaluated in both cohorts of gMG patients
Results indicate potential therapeutic benefits of rese-cel therapy in gMG.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial evaluates efficacy and safety of rese-cel in generalized myasthenia gravis, suggesting potential therapeutic benefits.

Abstract

RESET-MG (NCT06359041) is a Phase 1/2 trial evaluating the safety and efficacy of rese-cel in 2 independent cohorts of anti-AChR-antibody-positive and anti-AChR-antibody-negative gMG.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Habib et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf32afaef96ed7f055ae8 https://doi.org/10.1212/wnl.0000000000215393

View at Publisher

Ask AI

Bookmark

Share

RESET-MG: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB-CD19-CAR T Cell Therapy in Generalized Myasthenia Gravis (gMG) (S14.003)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

RESET-MG: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB-CD19-CAR T Cell Therapy in Generalized Myasthenia Gravis (gMG) (S14.003)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading